Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion as the FDA introduces a clearer regulatory framework for psychedelic drug development. The deal adds the Phase III depression candidate BPL-003 to Lilly’s neuroscience pipeline. More importantly, the
